10X Genomics (TXG) closed at $59.28 on November 6, 2026, up 2.1% from the previous close, on volume of 4,347,079 shares (30-day average 3,772,069).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Ratio Call Spread 1 by 2 | 20-Nov-2675[2x] : 85 C | 3,312 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Escalating Governance Burdens and Limited D&O Coverage Put 10x Genomics’ Financials at Risk
TipRanks (Sat, 7-Nov 1:00 AM ET)
10x Genomics (TXG) Receives a Hold from Bank of America Securities
TipRanks (Sat, 7-Nov 12:36 AM ET)
10x Genomics (TXG) Receives a Buy from Canaccord Genuity
TipRanks (Fri, 6-Nov 9:57 AM ET)
Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)
TipRanks (Fri, 6-Nov 9:43 AM ET)
UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)
TipRanks (Fri, 6-Nov 9:24 AM ET)
RBC Capital Keeps Their Hold Rating on 10x Genomics (TXG)
TipRanks (Fri, 6-Nov 9:22 AM ET)
10x Genomics GAAP EPS of -$0.15 beats by $0.11, revenue of $150.7M beats by $2.85M
Seeking Alpha News (Thu, 5-Nov 4:40 PM ET)
10x Genomics Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 5-Nov 4:05 PM ET)
10x Genomics launches Sentira Single Cell to bring agentic AI into Chromium analysis workflows
Market Chameleon (Mon, 2-Nov 4:34 AM ET)
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
PRNewswire (Mon, 2-Nov 9:00 AM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of November 6, 2026, TXG stock price climbed to $59.28 with 4,347,079 million shares trading.
TXG has a beta of 1.43, meaning it tends to be more sensitive to market movements. TXG has a correlation of 0.06 to the broad based SPY ETF.
TXG has a market cap of $7.72 billion. This is considered a Mid Cap stock.
Last quarter 10X Genomics reported $151 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.08.
In the last 3 years, TXG traded as high as $102.81 and as low as $6.78.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): VTI, VB, IWM, ARKG, VBK.
TXG has outperformed the market in the last year with a return of +356.0%, while the SPY ETF gained +10.8%. In the last 3 month period, TXG beat the market returning +30.0%, while SPY returned -4.1%. However, in the most recent 2 weeks TXG has underperformed the stock market by returning -17.1%, while SPY returned -3.2%.
TXG support price is $54.46 and resistance is $61.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.
